News

Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing. �South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Sun Pharmaceuticals Industries announced that the 34th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.